Scripto-Tokai Corp. v. Gillette Co.

788 F. Supp. 439, 22 U.S.P.Q. 2d (BNA) 1678, 1992 U.S. Dist. LEXIS 3625, 1992 WL 57601
CourtDistrict Court, C.D. California
DecidedMarch 20, 1992
DocketCV 91-2862 WJR (JRx)
StatusPublished
Cited by3 cases

This text of 788 F. Supp. 439 (Scripto-Tokai Corp. v. Gillette Co.) is published on Counsel Stack Legal Research, covering District Court, C.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Scripto-Tokai Corp. v. Gillette Co., 788 F. Supp. 439, 22 U.S.P.Q. 2d (BNA) 1678, 1992 U.S. Dist. LEXIS 3625, 1992 WL 57601 (C.D. Cal. 1992).

Opinion

MEMORANDUM AND ORDER

REA, District Judge.

This is a declaratory judgment action to clarify counter-plaintiff The Gillette Company’s (“Gillette’s”) right to recover damages, in its counterclaim for patent infringement, against counter-defendant Scripto-Tokai Corporation. Counter-defendant Scripto-Tokai Corporation is the successor by merger to Scripto, Inc.

The counter-defendant’s motion to clarify Gillette’s right to recover damages came on regularly for hearing before the Court on March 2, 1992. After full consideration of the documented evidence and authorities submitted by the parties, and oral argument of counsel, Scripto-Tokai Corporation’s motion is hereby denied.

BACKGROUND

The instant action involves a patent dispute concerning erasable inks for ball point pens.

Gillette pioneered and patented two erasable ink technologies. The first technology contains rubber (“rubber-based ink”). In 1979, Gillette marketed an erasable ink pen using the rubber-based ink. By mid-1980, Scripto, Inc. (a predecessor of Scripto-To-kai, Corporation) entered the market to compete against Gillette with a rubber-based erasable ink pen. Litigation between the companies ensued, and was settled in 1981. As part of that settlement, Scripto, Inc. took a non-exclusive license under Gillette’s rubber-based erasable ink patent. This is not at issue here.

Gillette’s second patented technology contains thermoplastic block copolymers (“block copolymer-based ink”). Gillette has never marketed erasable pens containing the block copolymer-based ink. Scripto, Inc., and later Scripto-Tokai Corporation (collectively “Scripto”), marketed erasable pens that were filled with block copolymer-based ink. The patents for the block copo-lymer-based ink are at issue in the instant action.

Both Gillette and Scripto have patents for erasable inks containing thermoplastic block copolymers. However, Gillette alleges that the block copolymer-based ink formula contained in the erasable pens sold by Scripto is covered by patents owned by Gillette.

During the period of alleged infringement, Scripto and Gillette were the only two participants in the erasable ink pen *441 market. While Scripto used block copolymer-based technology for the erasable ink in its pens, Gillette used its patented rubber-based technology for the erasable ink in the pens it sold. Scripto sold its block copolymer-based erasable ink pens in direct competition with Gillette’s rubber-based erasable ink pens.

Scripto brought this action for declaratory relief seeking a determination that the two patents owned by Gillette for “Erasable Inks Containing Thermoplastic Block Copolymer,” (U.S. Letters Patents Nos. 4,390,646 (Ferguson) and 4,891,927 (Farmer)), are invalid, unenforceable, and not infringed by Scripto. Gillette has counterclaimed alleging that Scripto infringed those patents, and claims damages for lost profits ranging from 20 million to 40 million dollars.

In the instant action, Scripto has moved for an order clarifying the rights of Gillette to recover damages on its counterclaim. Scripto alleges that, because Gillette never has marketed pens containing the ink covered by the patents-in-suit, (i.e., the block copolymer-based ink), any recovery by Gillette should be limited to reasonable royalties. Further, Scripto claims that the fact that Gillette exploits the relevant market by selling a product not covered by the patents-in-suit precludes the award of lost profits.

DISCUSSION

Counter-defendant Scripto has moved this Court for an Order precluding Gillette, as a matter of law, from claiming or recovering damages for lost profits on its counterclaim for patent infringement. Scripto makes this motion to clarify issues pursuant to Rule 16(c)(1) of the Federal Rules of Civil Procedure, which provides that participants at a pretrial conference may take action with respect to simplification of the issues.

Scripto advances two arguments in its attempt to establish, as a matter of law, that Gillette’s right to recover damages is limited to reasonable royalties. First, Scripto argues that Gillette is precluded by law from recovering lost profits damages because it has never commercially exploited the patents-in-suit. Second, Scripto argues that Gillette is precluded from seeking lost profits damages because rubber-based erasable inks were acceptable nonin-fringing substitutes for the patented inks.

A. A Patent Owner Is Not Precluded From Recovering Lost Profits From the Infringement Of Its Patent By The Fact, Alone, That The Patent Owner Has Not Marketed A Product Covered By The Patent.

The standard for damages for patent infringement is set forth in § 284 of the Patent Act. Section 284 provides that a patent owner whose patent has been infringed is entitled to “damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer, together with interest and costs as fixed by the court.” 35 U.S.C. § 284.

To be entitled to damages beyond a reasonable or established royalty, a claimant must prove his actual damages caused by the illicit competition of an infringer. Water Technologies Corp. v. Calco Ltd., 850 F.2d 660, 671, 7 U.S.P.Q.2d 1097, 1106 (Fed.Cir.1988). The owner must establish a factual basis for causation, i.e., that but for the infringer’s improper acts, he would have made greater sales, charged higher prices or incurred lower expenses. Id.; see also, Lam, Inc. v. Johns-Manville Sales Corp., 718 F.2d 1056, 1065, 219 U.S.P.Q. 670, 675, (Fed.Cir.1983). Causation need be proved only as a reasonable probability. Id.; Water Technologies Corp., 850 F.2d at 671, 7 U.S.P.Q.2d at 1106.

Where the patent owner and the infringer were the only suppliers of a unique and demanded product, and the owner had or could have acquired the capacity to meet the full demand, an inference that the patent owner lost sales equal in quantity to those actually made by the infringer may arise. Water Technologies, 850 F.2d at 671, 7 U.S.P.Q.2d at 1106 (summarizing 5 D. Chisum, Patents § 20.03[1], at 20-72, and judicial precedent, citations *442 omitted). Moreover, when the amount of the damages cannot be ascertained with precision, any doubts regarding the amount must be resolved against the infringer. Lam, 718 F.2d at 1065, 219 U.S.P.Q. at 675.

Scripto asserts incorrectly that Federal Circuit precedent has established, as a rule of law, that a patent owner is barred from recovering lost profits damages, if it did not market the patented product during the period of the alleged infringement. Scripto relies on three Federal Circuit cases in which the patentee was denied lost profits damages. However, these cases do not support Scripto’s position.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McGinley v. Franklin Sports, Inc.
192 F. Supp. 2d 1214 (D. Kansas, 2002)
Hall v. Doering
997 F. Supp. 1445 (D. Kansas, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
788 F. Supp. 439, 22 U.S.P.Q. 2d (BNA) 1678, 1992 U.S. Dist. LEXIS 3625, 1992 WL 57601, Counsel Stack Legal Research, https://law.counselstack.com/opinion/scripto-tokai-corp-v-gillette-co-cacd-1992.